Information filters

  • TIES®
  • Corporate
  • Job postings
  • Articles
  • Patients
  • General

Latest update on the TIES® Solution – May 2020

Message from Ostomycure CEO, Graeme Smith.

The interest in our TIES solution for permanent ileostomy patients is growing globally. Our clinical study to prove safety and efficacy was well underway until the impact of COVID-19 halted most elective surgery in Europe.

Our strategy has been to expand the clinical sites participating in the study and we have gone from 2 sites in 1 country (UK) to negotiating with 18 sites in 4 countries (Austria, Poland, Sweden and the UK) with more pending.

“In today’s Europe of changing and stricter safety and regulatory protocols, we are committed to do whatever it takes to bring the lifestyle changing TIES ileostomy lid solution to as many people as possible. Conventional stoma options have changed very little in the last 30 years and our goal is to provide additional options for permanent ileostomy patients” stated Graeme Smith.

As soon as clinical studies are given the green light to restart in Europe OstomyCure will be ready to support sites around the EU to participate in the clinical study.

New Stockholm office


OstomyCure has moved its Stockholm operations from Kista to the Karolinska Campus area in Solna in the heart of the bustling Stockholm life science scene.

First Patients enrolled in the C03 clinical study in the UK


Today the first patient was enrolled in the TIES03 study of the OstomyCure Transcuteous Implant Evacuation System (TIES®).

OstomyCure® AS receives the most sought-after Horizon 2020 EU grant of € 2.5 Mio.


OstomyCure AS® has received a EU grant of € 2.5 Mio. via the Horizon 2020 Project.

Large clinical study started in UK and Sweden


Approval for multicenter study “TIES-C03” in major university hospitals in Leeds, UK & Umeå, Sweden.

Latest update on TIES Solution


Message from CEO Ostomycure Dr Benedict Broenniman M.D.

OstomyCure AS Appoints new Chief Medical Officer


OstomyCure today announced the appointment of Cindy Wong, M.D. as Chief Medical Officer (CMO).

Article in IA Journal: Issue 233 Autumn 2016


OstomyCure AS has been published in The Ileostomy & Internal Pouch Support Groups latest issue of the IA Journal.

Experienced Chief Commercial Officer Joins OstomyCure AS


OstomyCure AS engages Morten Gunvad, currently founder and Head of GP Consulting GmbH, as Chief Commercial Officer of the TIES® System.

The TIES® System represented at major political event


The TIES® Implant and Lid will be represented at Almedalsveckan, an annual political event taking place in Visby, Sweden.